Takeda, astellas and sumitomo mitsui banking announce master agreement to establish joint venture company for incubation of early drug discovery programs

Tokyo , april 22, 2024 /prnewswire/ -- takeda pharmaceutical company limited (tse: 4502/nyse: tak, president and ceo; christophe weber, "takeda"), astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, "astellas"), and sumitomo mitsui banking corporation (president & ceo: akihiro fukutome, "smbc") today announced that the three companies signed a master agreement on april 22, 2024, to establish a joint venture company. the new company will be dedicated to the incubation*1 of early drug discovery programs, primarily originating from japan and toward the creation of innovative therapeutics.
TAK Ratings Summary
TAK Quant Ranking